目的 观察胶体酒石酸铋胶囊联合美沙拉秦治疗溃疡性结肠炎的临床效果。方法 选择2017年2月—2019年3月在郑州大学附属郑州中心医院治疗的溃疡性结肠炎患者79例，随机分成对照组（40例）和治疗组（39例）。对照组口服美沙拉秦肠溶片，1.5 g/次，3次/d。治疗组在对照组的基础上口服胶体酒石酸铋胶囊，3粒/次，4次/d。两组患者均连续治疗4周。观察两组患者临床疗效，同时比较治疗前后两组患者白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、IL-10、一氧化氮（NO）、过氧化脂质（LPO）和超氧化物歧化酶（SOD）水平，及临床症状缓解时间和溃疡性结肠炎活动度指数（DAI）。结果 治疗后，对照组临床有效率72.40%，显著低于治疗组的92.31%，两组比较差异有统计学意义（P<0.05）。治疗后两组患者IL-6、TNF-α、NO和LPO水平均显著降低（P<0.05），而SOD和IL-10水平显著升高（P<0.05）；且治疗后治疗组患者这些指标水平明显比对照组好。治疗后，两组患者DAI水平均显著降低（P<0.05），且治疗组明显比对照组低（P<0.05）。治疗后，治疗组黏液脓血便缓解时间和腹泻缓解时间明显比对照组短（P<0.05）。结论 胶体酒石酸铋联合美沙拉秦治疗溃疡性结肠炎，可纠正促炎因子，缓解氧化应激反应，改善腹泻等临床症状。

Objective To observe the clinical effect of Colloidal Bismuth Tartrate Capsules combined with mesalazine in treatment of ulcerative colitis. Methods Patients (79 cases) with ulcerative colitis in Zhengzhou Central Hospital Affiliated of Zhengzhou University from February 2017 to March 2019 were randomly divided into control (40 cases) and treatment (39 cases) groups. Patients in the control group were po administered with Mesalazine Enteric-coated Tablets, 1.5 g/time, three times daily. Patients in the treatment group were po administered with Colloidal Bismuth Tartrate Capsules on the basis of the control group, 3 grains/time, four times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the levels of IL-6, TNF-α, IL-10, NO, LPO and SOD, the relief time of clinical symptom and DAI in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 72.40%, which was significantly lower than 92.31% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the levels of IL-6, TNF-α, NO, LPO in two groups were significantly decreased (P<0.05), but the levels of IL-10 and SOD were significantly increased (P<0.05), and these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the DAI level in two groups was significantly decreased (P<0.05), and which in the treatment group were significantly lower than that in the control group (P<0.05). After treatment, the remission time of mucinous purulent bloody stool and diarrhea in the treatment group was significantly shorter than that in the control group (P<0.05). Conclusion Colloidal Bismuth Tartrate Capsules combined with mesalazine in treatment of ulcerative colitis can correct the imbalance of pro-inflammatory and anti-inflammatory factors, alleviate oxidative stress reactions, and improve clinical symptoms such as diarrhea.

R975

河南省高等学校重点科研项目（19A320079）